VVM
ALGS icon

Versant Venture Management’s Aligos Therapeutics ALGS Stock Holding History

Versant Venture Management’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-58,317
Closed -$510K – 7
2024
Q2 		$510K Sell
58,317
-34,498
-37% -$607K 0.66% 8
2024
Q1 		$2.27M Hold
92,815
– – 2.2% 7
2023
Q4 		$1.54M Hold
92,815
– – 0.4% 7
2023
Q3 		$1.73M Hold
92,815
– – 0.92% 7
2023
Q2 		$2.25M Hold
92,815
– – 2.67% 7
2023
Q1 		$2.03M Hold
92,815
– – 4.23% 6
2022
Q4 		$2.21M Hold
92,815
– – 4.58% 6
2022
Q3 		$2.55M Hold
92,815
– – 4.35% 5
2022
Q2 		$2.81M Hold
92,815
– – 4.3% 6
2022
Q1 		$4.99M Hold
92,815
– – 4.98% 8
2021
Q4 		$27.5M Hold
92,815
– – 14.73% 4
2021
Q3 		$36M Hold
92,815
– – 14.9% 4
2021
Q2 		$47.3M Sell
92,815
-38,879
-30% -$24.8M 15.67% 3
2021
Q1 		$74.9M Hold
131,694
– – 14.59% 3
2020
Q4 		$91M Buy
+131,694
New +$64.1M 9.45% 3

Other funds holding ALGS

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Versant Venture Management's ALGS Position: Q3 2024 in Review

Versant Venture Management sold out of Aligos Therapeutics (ALGS) in Q3 2024, closing a stake of 58,317 shares — an estimated $510K sold.

Versant Venture Management first reported a position in ALGS in Q4 2020 and held it in 15 quarters. The position peaked at $91M in Q4 2020. 27 funds tracked by Wall St. Rank hold ALGS as of Q3 2024.

  • Versant Venture Management reported no remaining Aligos Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Versant Venture Management sold 58,317 Aligos Therapeutics shares in Q3 2024, an estimated $510K.
  • Versant Venture Management first reported a position in Aligos Therapeutics in Q4 2020 and held it in 15 quarters.
  • Versant Venture Management's Aligos Therapeutics position peaked at $91M in Q4 2020.
  • 27 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q3 2024.

Based on Versant Venture Management's 13F filing for Q3 2024, filed 8 Nov 2024.